User Notice: The site will be occasionally unavailable due to scheduled maintenance this weekend. Please accept our apologies for any inconvenience.

Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron Group Plc LSE:RENE London Ordinary Share GB00BF5G6K95 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.00 -0.67% 147.50 145.00 150.00 149.50 147.50 149.50 68,911 16:09:39
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 6.1 -13.9 -35.9 - 84

Reneuron Share Discussion Threads

Showing 8176 to 8200 of 8300 messages
Chat Pages: 332  331  330  329  328  327  326  325  324  323  322  321  Older
DateSubjectAuthorDiscuss
11/2/2021
09:22
Keeps going from full cream to semi-skinned and eventually fully skimmed - pretty soon it won't colour your tea!
deutsch4
11/2/2021
08:34
Agreed. As Boards tend to set targets they expect to satisfy, I view this as very good news. Nice work if you can get it, though, particularly for the CEO and CFO.
dickbush
11/2/2021
08:10
Very nice option vesting target Stock has to triple!
the stigologist
10/2/2021
17:19
Another tick up day. Market is starting to pay some attention
ayl30
10/2/2021
08:33
hxxps://www.cityam.com/israeli-hospital-says-it-may-have-found-covid-19-cure-as-all-treated-patients-make-full-recovery/?utm_content=bufferb68fa Is this relevant to RENE? Thanks
felix99
08/2/2021
19:14
Chart seems to be ready to turn after retesting the breakout resistance level as support
the stigologist
07/2/2021
01:35
Hmm.... Interesting. If this makes its way into the widestream media it may generate more interest in exesomes and thereby benefit RENE: A protein known as CD24 is delivered to the lungs by exosomes in the drug, which helps to rebalance the immune system and prevent it from overreacting to the virus. However, should'nt it be "drug in the exosomes", not the other way round? Https://news.yahoo.com/israeli-covid-drug-cured-30-191709164.html?.tsrc=daily_mail&uh_test=2_15
lauders
06/2/2021
10:27
Same could be said of you?😂 well, changed perhaps? Any link to the interview?
rayrac
06/2/2021
05:54
Great interview by Michael Hunt. I assume he doesn’t abbreviate his first name.......
wonker26
05/2/2021
22:56
More than a technical bounce for me. Sounds rather bullish on prospects for Rene! Pleased to be a small participant in its future.
rayrac
05/2/2021
12:42
Think it's just a technical bounce as it retested downtrend line we broke out of Maybe Myles McNulty finished his selling to buy 4D ? We are overdue news on the Pharma collaborations 'promised' for Q1 if not january
the stigologist
05/2/2021
12:18
Not one to ramp but something coming down the tracks?
loafofbread
05/2/2021
10:29
Interesting buying going on. Long may it continue!
loafofbread
02/2/2021
17:46
Must hurt.
small crow
01/2/2021
22:57
Schroder UK Public Private Tst plc Agreement for sale of assets 27/01/2021 7:00am UK Regulatory (RNS & others) Woodford Patient Capital (LSE:WPCT) Historical Stock Chart From Jan 2021 to Feb 2021 Click Here for more Woodford Patient Capital Charts. TIDMSUPP RNS Number : 9819M Schroder UK Public Private Tst plc 27 January 2021 Schroder UK Public Private Trust plc (the "Company") Agreement for sale of assets The Company (LSE: SUPP) is pleased to announce that it has signed a sale and purchase agreement for the sale of a basket of seven assets (the "Sale Portfolio") to Rosetta Capital VI, LP (the "Buyer"), an investment fund managed by the UK-based life science venture capital firm Rosetta Capital Limited, for a total acquisition price of GBP49.0 million (the "Transaction"). The Sale Portfolio consists of the Company's entire holdings in Carrick Therapeutics, Mission Therapeutics, PsiOxus Therapeutics and Mereo BioPharma and partial holdings in Inivata, Immunocore and ReNeuron. The agreed acquisition price represents a discount of 22 per cent to the aggregate valuation for those holdings reflected in the Q3 2020 Net Asset Value ("NAV") as at 30 September 2020 (as published on 3 December 2020) or a discount of 19% per cent adjusted for relevant foreign exchange rate changes as of 25 January 2021. The Buyer has also agreed to pay approximately GBP2.9 million to the Company representing the value of certain follow-on investments made by the Company with respect to holdings contained in the Sale Portfolio during January 2021. In total, the Company expects to receive initial proceeds from the Transaction of approximately GBP51.9 million. Furthermore, given the recent news of Immunocore filing for an initial public offering ("IPO"), the Company has agreed with the Buyer an earn-out under which the Company might receive an additional contingent payment of up to GBP5.0 million subject to the Immunocore stake acquired by the Buyer exceeding certain value thresholds at the Buyer's future exit of the investment. The Company had previously agreed to a lock-up period under which it would not sell its entire holding for a period of 6 months from the date of the IPO. The Buyer has agreed to be bound by the restrictions of a lock-up agreement on the same terms as the Company. The Company will remain subject to the lock-up for the proportion of the holding it is retaining. In addition, the Company and the Buyer have agreed to a potential adjustment to the acquisition price in the event of significant changes in value of the listed portfolio companies Mereo BioPharma and ReNeuron on an aggregated basis by the date of completion of the Transaction. The Company does not currently expect the potential acquisition price adjustment, if any, to be significant in the context of the overall transaction. The closing of the Transaction is subject to customary closing conditions. The Company expects the completion to occur in late February or March 2021. The valuation impact of the Transaction is expected to be reflected in the NAV of the Company as at 31 December 2020, which is expected to be announced in April 2021. A significant proportion of the expected proceeds will be used to pay down a meaningful portion of the Company's outstanding debt under its credit facility whereby the current term loan will convert to a revolving credit facility. In addition, the Company intends to use the additional liquidity to support some of its portfolio companies with follow-on capital and further optimise the portfolio composition by selectively investing into new opportunities Tim Creed and Ben Wicks, Portfolio Managers of the Company, jointly commented: "After the announcement of the acquisition of Kymab by Sanofi and the extension of the Company's credit facility by two years, this is the third very positive announcement for the Company so far in 2021. When we assumed the management of the Company's investment portfolio in December 2019, we communicated that our initial focus in the process of repositioning the portfolio would be to reduce the outstanding debt to a sustainable level and put the Company back into a position to support its portfolio companies with follow-on capital and selectively make new investments. The basket transaction being announced today is a further important milestone for the Company and delivers against that communicated goal. Together with the divestiture of Kymab, the Company expects to receive total proceeds of more than GBP115 million by the end of the first half of 2021. Also, we are delighted to welcome Rosetta Capital as co-shareholders in ReNeuron, Immunocore and Inivata and we welcome their expertise and experience. We are looking forward to continuing to work with the management teams of the Company's holdings in delivering sustainable value and positive long-term shareholder returns." Susan Searle, Chair of the Board of the Company, commented: "I am extremely pleased with the progress that Schroders have made since taking over the management of the portfolio. The three announcements made in 2021; the extension of our debt facility, a significant portfolio company cash exit and a portfolio sale put the Company in a solid position from which to grow in 2021. These events reflect the hard work of the team throughout 2020 and I look forward to seeing the team build on this encouraging positive progress in repositioning the Company's portfolio." Enquiries: Schroder Investment Management Limited
loafofbread
01/2/2021
14:52
I wouldn't call him dull Stig, he is very clear and straightforward with maybe just a touch of "dour" thrown in to the mix. Had hoped the RP stuff might get to market before the projected 2024/2025 that he predicts in the video. I am hoping for some news on the Exosomes front long long before then.
algernon2
27/1/2021
21:09
RENE due to present tomorrow but a Conf related video out now www.vimeo.com/498431522
the stigologist
27/1/2021
16:20
Bought a few more for 113p
volsung
18/1/2021
20:15
Golden Cross rapidly approaching
the stigologist
18/1/2021
12:51
With US market closed a good day to push this story to a bored US bio #FinTwit audience htTps://twitter.com/Stockonomist/status/1351146669862244365?s=20
the stigologist
18/1/2021
09:32
Algernon2. Let's hope detritus does not get used as a badge of honour in the next US election.
hashertu
18/1/2021
09:31
WOW ! just ex CSO of $80 Billion Gilead joining Board of EvOx htTps://twitter.com/Stockonomist/status/1351099292233170945?s=20
the stigologist
18/1/2021
08:46
Stealth breakout continues
the stigologist
16/1/2021
21:35
"someuwin" on another BB posted this interesting link: Http://www.pmlive.com/pharma_intelligence/After_years_of_potential,_cell_and_gene_therapy_is_ready_for_the_pharmaceutical_mainstream_1360242 It contains this section M&A activity surging With large pharmaceutical companies reluctant to miss out on such an important advance in medicine, M&A activity in the space has increased exponentially. In 2014-15, M&A deal values in this sector were $5bn, and in 2018-19, this surged 980% to a combined two-year total of $49bn. The cell therapy, gene therapy and tissue engineering sector raised $2.9bn in venture capital in 2018 – twice the 2017 amount. Recent examples of this trend can be seen in Roche’s December 2019 $4.8bn takeover of Spark Therapeutics, one of the first US gene therapy firms to succeed in obtaining FDA approval – in this case for a project that can treat inherited vision loss. Another example is Biogen’s $800m acquisition of Nightstar’s late-stage gene therapy assets for retinal disease – NSR-REP1 and NSR-RPGR. Both deals represent well- capitalised pharma giants paying large sums for completed, or nearly completed, final products, giving the buyer an almost guaranteed product to start manufacturing, branding and distributing immediately. Such deals often benefit all parties involved – sellers may well have been struggling under the costs to pursue trials and approvals (even for extremely promising candidates) and would have faced extreme financial pressure in trying to bring a treatment to market. Seems many are predicting this will be the eventual fate of RENE. Time will certainly tell!
lauders
16/1/2021
13:42
Yup also just watched the hour and a bit long presentation. Very good news to know the exosomes are still a hot topic and getting hotter all the while apparently. Not too long ago they were just the waste products of cells and considered detritus. Great to realise this "detritus" may make the Company a multi-bagger at some point in the next 2 years due to the significant increase of interest in them. And crossing the blood-brain barrier = winner.
algernon2
Chat Pages: 332  331  330  329  328  327  326  325  324  323  322  321  Older
ADVFN Advertorial
Your Recent History
LSE
RENE
Reneuron
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210509 17:25:22